BLRX · BioLineRx Ltd.
Market Cap
$12.23M
Shares
4.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.76
Open$2.89
Day$2.60–2.89
52W close$2.18–4.44
Avg vol 30d18K
Short int135K · 3.1% float · 19.8d
Short vol12%
Last earningsSep 30, 2025
DataJan 2025–Sep 2026
Raw chart and full-history price indicators begin at the captured split on Jan 30, 2025; bars on opposite sides are not compared.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Neutral
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
Death cross
Price vs 200-day avg
−5%
below
Price vs 50-day avg
−5%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
26%
mid-range
Momentum
relative strength
1-month return
0%
trailing
6-month return
+5%
trailing
YTD return
0%
this year
Relative strength
−8%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
Death cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.08% of float · ▼ -0.2% MoM · 19.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
14 holders — mid 3-yr range
Squeeze score
57
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−51%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
Death cross
Bearish
Price vs 200-day avg
−5%
Bearish
Price vs 50-day avg
−5%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
26%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
Death cross
50d $3 › 200d $3 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +3 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
3.08% of float · ▼ -0.2% MoM · 19.8 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
14 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 26%
Range high $4
vs 200-day avg -5%
vs 50-day avg -5%
50-day below 200-day death cross
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLRX
this stock
BioLineRx Ltd.
|
$12.23M | -0.4% | — | — | 3.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
MRNA
Moderna, Inc.
|
$61.59B | +423.1% | +4.3% | — | 13.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
14
- % held
- 2.4%
- Net QoQ
- +75.8K sh
- Top holder
- SUSQUEHANNA INTERNATIONAL…
Held
Float
Short & Settlement
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jan 30, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLRX | -3.2% | +0.0% | +4.6% | -1.4% | -0.4% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -2.6% | +1.2% | -8.1% | -0.7% | -12.1% |
Key facts
CIK
1498403
CUSIP
09071M304
13F (30d)
12 filings
12 filers
Visit website
Investor relations